Next steps unclear as Roche's inclacumab meets Phase II endpoint in post-angioplasty study

Roche's inclacumab (RG1512) reduced heart tissue damage in patients with acute coronary syndromes who were dosed with the p-selectin antagonist prior to angioplasty in a Phase II clinical trial, but the Swiss drug maker has not indicated how or whether it will move forward with the monoclonal antibody licensed from Genmab.

Inclacumab met the primary endpoint - a decrease in levels of troponin I, an indicator of heart damage - in the 530-patient, placebo-controlled SELECT trial